3Joseph LN, Bablian VL, Allen NC, et al. Risk factor modification in stroke prevention: the experience of a stroke clinic. Stroke, 1999, 30(1): 16-20.
4Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 1990, 335(8693): 827-838.
5Hess DC, Demchuk AM, Brass LM, et al. HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. Neurology, 2000, 54(4): 790-794.
6Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: Stroke prevention in patients with nonvalrular atrial fibrillation. Neurology, 1998, 51 (3):671-673.
7Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med, 1997, 336(4): 251-257.
8Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid stenosis. JAMA,1995, 273(18): 1421-1428.
9Fiore MC, Bailey WC, Cohen SU, et al. Smoking cessation: Clinical practice guideline no.18. AHCPR publication no.96-0692. In: Pockcille MD. US Department of Health and Human services, Public Health Service, Agency for Health Care Policy and Research, 1996.
10American Diabetes Association. Clinical practice recommendations 1998. Diabetes Care, 1998, 21(suppl 1): S1-S89.
